<DOC>
	<DOCNO>NCT02197702</DOCNO>
	<brief_summary>In 7-month randomized control trial , child age 1-6 year asthma attack trigger mostly cold , receive high dose vitamin D placebo every 3.5 month usual clinic visit . This study test whether child receive high dose vitamin D le frequent less severe asthma exacerbation compare receive placebo.The study also document safety profile strategy .</brief_summary>
	<brief_title>Vitamin D Preschoolers With Viral-induced Asthma</brief_title>
	<detailed_description>Design : A multicenter triple-blind randomized parallel-group , placebo-controlled trial vitamin D3 supplementation . Children age 1-5 year ( ) physician-diagnosed asthma , predominantly trigger upper respiratory tract infection ( URTIs ) , ( ii ) ≥4 report URTIs past year , ( iii ) ≥1 exacerbation require OCS ( recognise marker moderate severe exacerbation ) past 6 month ≥2 past 12 month , randomly allocate one two treatment block 4-6 , stratified recruitment site : Intervention group ( n=432 ) —100,000 IU oral vitamin D3 ; control group ( n=432 ) —identical placebo , 2 oral dos , 3.5 month apart . Co-intervention asthma therapy ( preventive pre-emptive ICS ) leave discretion physician document . Children follow every 3.5 month per usual practice , home visit 10 day bolus , urine blood sample urinary calcium : creatinine ratio , serum vitamin D , marker calcium metabolism , mechanistic exploration . A validated diary serve document intensity severity exacerbation . In two site , preschool lung function document ( ≥ 3yrs ) . Outcomes : Primary endpoint-number exacerbation require rescue oral corticosteroid ( OCS ) per child , document medical pharmacy record . Secondary outcome : duration severity exacerbation ( symptom &amp; β2-agonist use , diary ; emergency visit , medical record ) , parental functional status ( validate instrument ) , asthma therapy intensification health care direct cost ( health record &amp; parent report ) . Safety , mechanistic , exploratory outcome : hypercalciuria , calcium metabolism , excess vitamin D , change serum gene expression 10 day ( first 25 patient ) ; change baseline 7 month preschool lung function ( 2 site ) . Based 3 publish RCTs , sample 432 per arm ( 400+7.5 % attrition ) provide 80 % power ( 2-tailed alpha 5 % ) detect 25 % reduction number exacerbation require OCS/child ( 0.55 vs. 0.4125 ) .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>age 15 year physiciandiagnosed asthma per Global Initiative Asthma ( GINA ) guideline URTIs main asthma trigger ( parental report ) ≥4 URTIs past 12 month ( parental report ) ≥1 asthma exacerbation require rescue oral corticosteroid ( OCS ) past 6 month ≥2 past 12 month intake intention use 400 IU/day vitamin D supplement extreme prematurity ( &lt; 28 week gestation ) infants &lt; 12 month age vitamin D supplementation breastfed recent ( &lt; 1 year ) immigrants region high risk rickets child vitamin D restrictive diet e.g . vegan chronic respiratory disease ( bronchopulmonary dysplasia ; cystic fibrosis ) condition ( ) alter calcium vitamin D metabolism/absorption ( hypo/hyperparathyroidism , kidney/liver disease , inflammatory bowel disease ) medication interfere vitamin D metabolism ( antiepileptic , diuretic , antacid , antifungal drug ) vitamin D supplementation &gt; 1000 IU/ day last 3 month anticipate difficult followup ( unable attend clinic visit ; plan leave province ) .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>RCT</keyword>
	<keyword>asthma</keyword>
	<keyword>pediatric</keyword>
	<keyword>virus</keyword>
	<keyword>corticosteroid</keyword>
</DOC>